Latest Trials Latest NewsFAQ

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)

Phase 2

Completed

Conditions: Congestion, Nasal

Interventions: Device: Breathe Right Tan (small/medium) nasal strips
Other: Placebo nasal strip

First Posted Date: 2018-06-07

Last Posted Date: 2018-09-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 140

Registration Number: NCT03549117

Locations: 🇺🇸
Essex Testing Clinic, Inc, Verona, New Jersey, United States
🇺🇸
Radiant Research - Cincinnati, Cincinnati, Ohio, United States

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Nicotine Prototype Mini lozenge
Drug: Nicorette Mini Lozenge

First Posted Date: 2018-06-01

Last Posted Date: 2019-12-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT03543137

Locations: 🇺🇸
GSK Investigational Site, Lincoln, Nebraska, United States

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: FLUT/SAL
Other: UMEC/VI
Other: CAT
Other: mMRC
Device: Ellipta
Device: Diskus

First Posted Date: 2018-06-01

Last Posted Date: 2020-08-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 789

Registration Number: NCT03543176

Locations: 🇺🇸
GSK Investigational Site, Durham, North Carolina, United States

BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

Conditions: Dysphonia

Interventions: Drug: BOTOX

First Posted Date: 2018-06-01

Last Posted Date: 2021-10-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT03543150

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2018-06-01

Last Posted Date: 2024-05-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 153

Registration Number: NCT03544281

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Nicotine Prototype Mini lozenge
Drug: Nicorette Mini Lozenge

First Posted Date: 2018-05-30

Last Posted Date: 2020-03-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 46

Registration Number: NCT03541044

Locations: 🇺🇸
GSK Investigational Site, Lincoln, Nebraska, United States

A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults

Phase 2

Completed

Conditions: Dysentery, Bacillary

Interventions: Drug: Placebo
Biological: S.sonnei vaccine
Biological: S. sonnei 53G challenge strain

First Posted Date: 2018-05-17

Last Posted Date: 2020-07-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 71

Registration Number: NCT03527173

Locations: 🇺🇸
GSK Investigational Site, Cincinnati, Ohio, United States

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin frozen liquid
Drug: Belantamab mafodotin lyophilized powder

First Posted Date: 2018-05-16

Last Posted Date: 2024-10-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 221

Registration Number: NCT03525678

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: GSK2798745
Drug: Lipoplysaccharide from Escherichia Coli
Drug: Saline

First Posted Date: 2018-04-27

Last Posted Date: 2021-03-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 47

Registration Number: NCT03511105

Locations: 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany

Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)

Completed

Conditions: Sjogren's Syndrome

Interventions: Other: PSC questionnaire
Other: Interview
Other: PRFs

First Posted Date: 2018-04-18

Last Posted Date: 2019-01-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2223

Registration Number: NCT03501420

Locations: 🇬🇧
Adelphi Real World Investigational Site, Cheshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy